EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, RIGL: Rigel Pharmaceuticals

11 Dec 25 14:00
LAST:

42.29

CHANGE:
 1.07		OPEN:
40.95		HIGH:
43.58		ASK:
3.50		VOLUME:
206.7K
CHG(%):
2.60		PREV:
41.22		LOW:
40.60		BID:
2.79		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Dec 2540.9543.5840.6042.29206.7K
10 Dec 2542.5143.4541.1441.22416.0K
09 Dec 2542.4144.4641.9942.33455.4K
08 Dec 2547.8748.0039.6043.401.0M
05 Dec 2547.5749.9646.9848.92447.4K
04 Dec 2547.1348.5046.7647.38395.2K
03 Dec 2544.0947.3044.0947.21473.5K
02 Dec 2547.8247.8243.8144.41728.4K
01 Dec 2550.0250.2746.8047.26588.6K
28 Nov 2551.4552.2450.0650.49275.7K

PROFILE

Name:Rigel Pharmaceuticals
About:Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.rigel.com
CUSIP:766559108
CIK:0001034842
ISIN:US7665597024
FIGI:BBG000BPWTW7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:5.82 
Forward P/E:35.89 
PEG Ratio:0.00 
Price to Sales:2.11 
Price to Book:6.91 
Profit Margin:0.37 
Operating Margin:0.60 
Return on Assets:0.39 
Return on Equity:3.76 
EPS Ratio:5.43 
Revenue:267.92M 
EBITDA:109.3M 
Shares:17.94M 
Market Cap:758.57M 

TECHNICAL INDICATORS

MA5:43.613.1%
MA10:45.487.5%
MA20:45.377.3%
MA50:36.5715.6%
MA100:34.8521.3%
MA200:27.0256.5%
STO9:10.61 
STO14:8.71 
RSI14:46.96
WPR14:-90.14 
MTM14:-4.04
ROC14:-0.09 
ATR:3.46 
Week High:49.9618.1%
Week Low:39.606.8%
Month High:52.2423.5%
Month Low:34.0056.5%
Year High:52.2423.5%
Year Low:14.63189.1%

RECENT SPLITS

Date Ratio
27 Jun 20241-10
25 Jun 20031-9